## Review setup
- **Input scope** Full manuscript text (abstract, introduction, methods, results, discussion, conclusions) as provided
- **Assessment boundary** Scientific validity, technical soundness, and interpretive claims based solely on the supplied text; no external verification of data or figures beyond what is described
- **Shared manuscript claim summary** The authors report a novel de novo NR2F1 variant (c.452T>A, p.Met151Lys) in a 10-month-old female with severe neurodevelopmental delay and bilateral optic nerve pallor. They claim the variant disrupts transcriptional activity (via dual-luciferase assay) and may destabilize the zinc finger structure (via molecular dynamics simulation), thereby causing the severe phenotype and expanding the BBSOAS variant spectrum.
- **Visible evidence base** Clinical phenotyping (developmental scales, fundoscopy, MRI, echocardiography), whole-exome and Sanger sequencing, in silico pathogenicity predictions, ACMG classification, dual-luciferase reporter assay, molecular dynamics simulation (50 ns, GROMACS)
- **Missing materials affecting confidence** Raw sequencing data, variant filtering details (Supplementary Material 2 referenced but not provided), full figure data (Fig. 4a/b), statistical output details, AlphaFold structure identifiers, simulation convergence metrics beyond RMSD, and any negative controls for the luciferase assay

## Reviewer
- **Overall assessment** This manuscript presents a clinically well-characterized single case with a plausible novel NR2F1 variant and provides preliminary functional evidence of impaired transcriptional activity. The clinical description is thorough and the genetic workup is standard. However, the functional and computational evidence is preliminary, with several technical gaps that limit the strength of the causal claim. The manuscript is of interest to the BBSOAS and neurodevelopmental disorder community, but the evidence as presented does not fully establish the mechanistic link between the variant and the severe phenotype.
- **Who would be interested in the results, and why** Clinicians and geneticists specializing in neurodevelopmental disorders, particularly BBSOAS; researchers studying NR2F1 function, orphan nuclear receptors, and genotype-phenotype correlations. The case adds to the limited literature on severe NR2F1 variants in diverse populations, which is relevant for diagnostic and counseling purposes.
- **Major strengths** (1) Detailed clinical phenotyping with standardized developmental assessments; (2) clear genetic evidence of a de novo variant confirmed by Sanger sequencing; (3) inclusion of in vitro functional data (dual-luciferase) and computational modeling (MD) to support pathogenicity; (4) ACMG-based classification adds rigor; (5) discussion of genotype-phenotype correlations is relevant and appropriately cautious.
- **Major Concerns** See detailed items below.
- **Minor Comments** See detailed items below.
- **Technical failings that need to be addressed before the case is established** R1-M1 (functional assay completeness), R1-M2 (MD simulation rigor), R1-M3 (causal inference from single case)
- **Assessment against Nature-style criteria**  
  - **Originality** Moderate. The variant is novel, but the approach (single case, standard functional assay, MD simulation) is not methodologically innovative.  
  - **Scientific importance** Limited to a specialist audience; the case adds a data point but does not fundamentally advance understanding of NR2F1 biology or BBSOAS mechanisms.  
  - **Interdisciplinary readership** Low. The content is primarily clinical genetics with basic functional validation; unlikely to attract broad interdisciplinary interest.  
  - **Technical soundness** Partially adequate. Genetic and clinical methods are sound; functional and computational methods have gaps (see concerns).  
  - **Readability for nonspecialists** Acceptable. The manuscript is clearly written, though some technical sections (MD simulation) may be dense for clinical readers.
- **Recommendation posture** Supportive if technical concerns are resolved, particularly regarding the functional assay design and MD simulation rigor. Currently, the case is not fully established from the provided evidence.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Functional evidence
- **Claim pointer** "Dual-luciferase assays indicated this variant affects transcriptional activation" and "the variant affects the transcription of EGR1"
- **Evidence pointer** Results section, Fig. 4a; Methods section, "Dual-luciferase assay"
- **Concern** The dual-luciferase assay is described with minimal methodological detail. It is unclear whether the assay tested the variant's effect on a known NR2F1-responsive promoter (e.g., EGR1) in a dose-dependent manner, whether the construct was validated for expression, and whether the assay included a wild-type control with comparable expression levels. The figure shows a significant reduction relative to wild-type, but no data on transfection efficiency, protein expression, or replicate variability are provided. Additionally, the claim that the variant "affects transcriptional activation" is based on a single target gene (EGR1) without testing other known NR2F1 targets or assessing DNA-binding affinity directly.
- **Why it matters** The functional assay is the primary experimental evidence linking the variant to a mechanistic defect. Without rigorous controls and broader target testing, the conclusion that the variant disrupts transcriptional activity is under-supported, which weakens the causal link to the severe phenotype.
- **Resolution test** Provide detailed assay conditions, including promoter construct, transfection normalization, and expression validation. Include dose-response experiments, test multiple NR2F1 target promoters, and ideally perform electrophoretic mobility shift assays or chromatin immunoprecipitation to directly assess DNA-binding effects.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Computational evidence
- **Claim pointer** "The molecular dynamics analysis showed that this variant might affect the stability of the zinc finger structure within the NR2F1 DNA-binding domain" and "the Lys side chain formed a hydrogen bond with Cys106 in ZF1, increasing the zinc ion coordination distance"
- **Evidence pointer** Results section, "MD suggests p.Met151Lys affects the zinc finger structures"; Methods section, "Molecular dynamics simulation"
- **Concern** The MD simulation is described with insufficient detail to assess its validity. The methods state 50 ns simulations with GROMACS and the Gromos53a6 force field, but no information is provided on the starting structure (AlphaFold model), solvation box size, ion concentration, temperature/pressure coupling, or number of replicates. The claim of a hydrogen bond between Lys151 and Cys106 is based on a single simulation trajectory, and no statistical analysis (e.g., bond occupancy over time, free energy calculations) is presented. The RMSD value of 1.50 Å is mentioned as evidence of equilibrium, but this is not sufficient to establish conformational stability or functional impact.
- **Why it matters** The MD simulation is used to propose a structural mechanism for the variant's effect. If the simulation is not robustly designed or analyzed, the structural claim is speculative, which undermines the mechanistic interpretation.
- **Resolution test** Provide full simulation parameters, including starting structure, equilibration protocol, and replicate runs. Show time-series data for the hydrogen bond occupancy and zinc coordination distance, and ideally perform multiple independent simulations to confirm reproducibility. Consider free energy perturbation or umbrella sampling to quantify the impact on zinc binding.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Causal inference
- **Claim pointer** "The NR2F1 variant c.452T>A (p.Met151Lys) may genetically cause the severe clinical phenotypes observed in this patient"
- **Evidence pointer** Conclusions section; Discussion section
- **Concern** The manuscript asserts a causal relationship between the variant and the severe phenotype based on a single case. While the de novo occurrence and ACMG classification support pathogenicity, the absence of functional validation in relevant cellular or animal models, and the lack of comparison with other BBSOAS cases with similar variants, limits the strength of the causal claim. The authors acknowledge this in the limitations, but the conclusion is still stated with more certainty than the evidence warrants.
- **Why it matters** Overstating causality from a single case can mislead clinical interpretation and genetic counseling. The field requires robust genotype-phenotype correlations, which this study cannot provide alone.
- **Resolution test** Soften the causal language to "likely contributes to" or "is associated with." If possible, include additional cases with the same variant or functional studies in patient-derived cells or animal models to strengthen the evidence.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clinical data completeness
- **Affected element** Table 1
- **Evidence pointer** Table 1
- **Issue** The developmental assessment table lists "Personal socialization" and "Language ability" as "Not evaluated." This is a notable gap given the claim of severe neurodevelopmental delay, as language and social communication are core domains in BBSOAS.
- **Required correction** Provide any available data on these domains, or explicitly state why they were not assessed (e.g., age-appropriateness, patient cooperation).

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Variant interpretation
- **Affected element** ACMG classification
- **Evidence pointer** Results section, "Genetic testing results"
- **Issue** The ACMG criteria are listed (PS2, PM1, PM2, PP3), but the final classification is stated as "likely pathogenic" without specifying the full combination of criteria used. The manuscript does not mention whether additional criteria (e.g., PM3, PP2) were considered or why they were not applied.
- **Required correction** Provide a clear ACMG scoring table or narrative that lists all criteria considered and the final classification rationale.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Literature context
- **Affected element** Discussion
- **Evidence pointer** Discussion section
- **Issue** The discussion mentions that "additional cases with severe phenotypes strengthen the evidence that the genotype and phenotype correlate," but does not systematically compare the current case with previously reported BBSOAS cases with DBD variants.
- **Required correction** Add a brief comparison table or narrative summarizing phenotypes of previously reported DBD variants to contextualize the severity of this case.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Figure quality
- **Affected element** Fig. 4b
- **Evidence pointer** Fig. 4b
- **Issue** The MD simulation figure is described as showing "changes in NR2F1 protein with and without the variant," but the figure is not provided in the text. The red circle indicating a local structural change is not interpretable without the figure.
- **Required correction** Ensure the figure is included with clear labels and a legend that explains the structural change and the significance of the red circle.

- **Concern ID** R1-m5
- **Severity** Minor
- **Axis** Statistical reporting
- **Affected element** Fig. 4a
- **Evidence pointer** Fig. 4a
- **Issue** The figure legend states "*** P < 0.001" but does not specify the statistical test used or the number of independent experiments. The methods state one-way ANOVA, but the figure legend should be self-contained.
- **Required correction** Add the statistical test, sample size, and error bar definition to the figure legend.

## Risk / unsupported claims
- The claim that the variant "may genetically cause the severe clinical phenotypes" is not fully supported by the evidence; it is an inference from a single case with preliminary functional data.
- The specific structural mechanism (hydrogen bond with Cys106 increasing zinc coordination distance) is based on a single MD simulation and is not experimentally validated.
- The statement that the variant "affects transcriptional activity" is based on one target gene (EGR1) and lacks broader functional validation.
- The claim that the variant is "novel" is supported by absence from databases, but this is not confirmed against all possible sources (e.g., gnomAD, local databases).
- The clinical significance of the patent foramen ovale is mentioned but not discussed in relation to the phenotype; this is not a claim per se, but its inclusion without interpretation is unclear.